Unum Therapeutics Inc (NASDAQ:UMRX)’s share price was up 8.1% during mid-day trading on Wednesday . The stock traded as high as $0.98 and last traded at $0.93, approximately 229,443 shares traded hands during mid-day trading. A decline of 26% from the average daily volume of 310,344 shares. The stock had previously closed at $0.86.

Several brokerages recently commented on UMRX. Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Saturday, November 9th. Morgan Stanley reduced their target price on Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Unum Therapeutics has an average rating of “Buy” and an average price target of $8.30.

The company has a fifty day moving average of $0.72 and a 200 day moving average of $1.49. The firm has a market capitalization of $29.74 million, a P/E ratio of -0.67 and a beta of 1.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.96 and a quick ratio of 1.96.

Unum Therapeutics (NASDAQ:UMRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.07). Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%. The company had revenue of $1.02 million during the quarter, compared to the consensus estimate of $4.41 million. On average, sell-side analysts forecast that Unum Therapeutics Inc will post -1.42 EPS for the current year.

A number of hedge funds have recently made changes to their positions in UMRX. Paloma Partners Management Co bought a new stake in Unum Therapeutics in the second quarter valued at approximately $227,000. Jane Street Group LLC bought a new stake in Unum Therapeutics in the second quarter valued at approximately $132,000. Wedbush Securities Inc. bought a new stake in Unum Therapeutics in the third quarter valued at approximately $48,000. Susquehanna International Group LLP bought a new stake in Unum Therapeutics in the second quarter valued at approximately $62,000. Finally, Tower Research Capital LLC TRC bought a new stake in Unum Therapeutics in the third quarter valued at approximately $31,000. Institutional investors and hedge funds own 40.34% of the company’s stock.

Unum Therapeutics Company Profile (NASDAQ:UMRX)

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

See Also: Why do companies issue monthly dividends?

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.